

February 23, 2015



Second Sight to Present at the 27th Annual ROTH Conference on March 9, 2015

SYLMAR, Calif.--(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind patients, today announced that Dr. Robert Greenberg, President and Chief Executive Officer, will present at the 27th Annual ROTH Capital Partners Conference as follows:

Date: Monday, March 9, 2015
Time: 8:30 a.m. PST (11:30 a.m. EST)
Location: The Ritz-Carlton, Laguna Niguel, Track 2, Salon
2

The Company will also host one-on-one meetings throughout the day.

The presentation will be webcast live at the aforementioned time as well as archived for 90 days thereafter, via the Company's website at www.secondsight.com, under the Investors Section.

About Second Sight

Second Sight Medical Products, Inc. was founded in 1998 to create a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations such as RP. Second Sight's mission is to develop, manufacture, and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. The Company's Argus II retinal prosthesis is approved in the U.S. and Europe. Second Sight is developing the OrionTM cortical prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. The population of people potentially eligible for the future Orion cortical prosthesis in Germany is about 71,000. The company's headquarters are in Sylmar, California, and its European Headquarters are in Lausanne, Switzerland. For more information, please visit www.secondsight.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements". While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks

and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections contained within our final prospectus filed with the United States Securities and Exchange Commission on November 20, 2014. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

For Patient Inquiries:

Argus II hotline:

Germany: 0800-184-4321

International: 1 (818) 833-5027

US (toll free): 1 (855) 756-3703

patients@secondsight.com

or

Media Relations:

Pascale Communications, LLC

Audra Friis

917-519-9577

audra@pascalecommunications.com

or

Investor Relations:

Retail Investors:

MZ North America

Matt Hayden, Chairman

949-259-4896

matt.hayden@mzgroup.us

or

Institutional Investors:

In-Site Communications, Inc.

Lisa Wilson, President

212-452-2793

lwilson@insitecony.com

Source: Second Sight Medical Products, Inc.